Head-to-head evidence
AZD5462 vs R2R01
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Relaxin receptor (RXFP1) / relaxin · full Heart Failure pipeline
AZD5462
Developed by AstraZeneca
NCT06299826 · Phase 2 · completed
The study was randomized, double-blind, and placebo-controlled, with 375 participants across three AZD5462 dose groups and a placebo group. Its primary endpoint was a surrogate echocardiographic measure, and no primary-outcome results or statistical comparison are currently available.
R2R01
Developed by River 2 Renal
NCT06264310 · Phase 2 · completed
The study randomly assigned participants to R2R01 or placebo and used blinded treatment, but only 33 participants were enrolled across four groups. Its primary endpoint was safety and tolerability, and no primary-endpoint results or statistical comparison are posted, so the trial provides limited evidence at this time.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD5462's landscape · R2R01's landscape